Therefore, both previous studies and the current study have shown that EGFR mutations are more common to female, never-smoker and lung adenocarcinoma, and this group of people is more likely to benefit from EGFR-TKI drugs, which could help to choose the best therapeutic drugs for clinicians with a significant reference. Here, EGFR is linked to lung adenocarcinoma.